AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	382.76M +29.4%
Revenue (ttm)	236.25M +19.0%
Net Income	17.45M +50.3%
EPS	0.16 +59.1%
Shares Out	104.87M
PE Ratio	22.56
Forward PE	24.42
Dividend	0.02 (0.49%)
Ex-Dividend Date	Jun 18, 2025

Volume	1,373
Average Volume	7,372
Open	3.700
Previous Close	3.710
Day's Range	3.650 - 3.700
52-Week Range	2.410 - 3.800
Beta	0.43
RSI	54.60
Earnings Date	Feb 18, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.